Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744256 | 1.00 | KCNH2 (0.71) | KCNH2CCR2 | |
| SCHEMBL744284 | 0.92 | CCR2 (0.69) | KCNH2CCR2 | |
| SCHEMBL744285 | 0.92 | CCR2 (0.69) | KCNH2CCR2 | |
| SCHEMBL743860 | 0.90 | CCR2 (0.66) | KCNH2CCR2 | |
| SCHEMBL743861 | 0.90 | CCR2 (0.66) | KCNH2CCR2 | |
| SCHEMBL5234484 | 0.89 | CCR2 (0.81) | KCNH2CCR2 | |
| SCHEMBL765615 | 0.89 | CCR2 (0.81) | KCNH2CCR2 | |
| SCHEMBL743061 | 0.89 | CCR2 (0.81) | KCNH2CCR2 | |
| SCHEMBL743060 | 0.89 | CCR2 (0.81) | KCNH2CCR2 | |
| SCHEMBL13048798 | 0.89 | CCR2 (0.81) | KCNH2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2013-05-09 | — | — | US | claimed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | claimed |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2011-10-13 | — | — | US | claimed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| EP-2431357-A2 | 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors | Incyte Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116230-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | KCNH2 2991/4885CCR2 1/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | KCNH2 2930/4885CCR2 1/4885 |
| US-20110251168-A1 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CXCR3, CCR5 | KCNH2 2991/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.